Dr. Carl Nathan, chair of the department of microbiology and immunology and the R.A. Rees Pritchett Professor of Microbiology at Weill Cornell Medicine, has co-authored a review in Science on the immune protein interferon-gamma. He answered questions about its history and prospects as a therapeutic.

Dr. Andrea Card, assistant professor of medicine at Weill Cornell Medicine, has always embraced diversity, equity and inclusion, starting in the 1990s when she was a medical student—long before it became a priority across the country. This year, Dr. Card received the Bruce Laine Ballard Award at Weill Cornell Medicine’s Celebration of Diversity, part of the institution’s sixth annual Diversity Week, held April 15 in Griffis Faculty Club.

Cinthia Garcia was always passionate about science and medicine. The first in her family to complete post-secondary education, she earned a Bachelor of Science degree at Emmanuel College in Boston in 2018 and then became a laboratory manager at the UC San Diego School of Medicine. Still, she dreamed of a career as a physician-scientist, pursuing translational research with the potential to improve patient care. 

Weill Cornell Medicine scientists have developed an innovative human neuron model that robustly simulates the spread of tau protein aggregates in the brain—a process that drives cognitive decline in Alzheimer's disease and frontotemporal dementia. This new model has led to the identification of novel therapeutic targets that could potentially block tau spread.

The preclinical study, published April 5 in Cell, is a significant advancement in Alzheimer's disease research.

A team led by researchers at Weill Cornell Medicine has identified important drivers of the transformation of a type of blood cancer called follicular lymphoma from a slow-growing form to the aggressive form it takes in some patients.

The study, published March 7 in Cancer Cell, showed that while mutations affecting a gene-regulating complex called BAF can put the cancer on a dangerous trajectory, they also make follicular lymphoma highly susceptible to experimental BAF-inhibitor drugs.

A collaboration between Dr. Jedd Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, and Dr.

The 2024 Health Hackathon brought together 185 students with diverse backgrounds from Cornell and 26 other universities—in just 36 hours, they addressed critical safety challenges facing patients today.